Many patients on GLP-1s experience muscle atrophy, which can alter body composition and make weight fluctuations more noticeable (and as muscle helps reduce insulin resistance, muscle loss works against health metabolism)
Clinically and definitively, yes
The interaction is most significant during two periods: Treatment initiation: When you first start tirzepatide, the gastric emptying effect is new and your body has not adapted Dose escalation: Each time you increase your tirzepatide dose , the gastric emptying delay intensifies temporarily before your body adjusts Over time, as your body adapts to each dose level, the impact on gastric emptying partially normalizes
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
While breakouts are not listed as a recognized adverse effect in FDA prescribing information, some individuals report skin changes during therapy
The pain is not indicative of structural damage